ABBV vs MA: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Mastercard Incorporated — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Mastercard Incorporated · Financial Services
$498.66
+22.3% upside to fair value
High Conviction
Grade A-
QuantHub Verdict
MA has more upside to fair value
(+22.3%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MA |
| Current Price |
$208.05 |
$498.66 |
| Fair Value Estimate |
$217.50 |
$610.00 |
| Upside to Fair Value |
+4.5%
|
+22.3%
|
| Market Cap |
$367.9B |
$445.0B |
| Forward P/E |
14.9x
|
25.5x
|
| EV / EBITDA |
16.7x
|
22.4x
|
| Price / Sales |
6.1x
|
13.6x
|
| Price / FCF |
20.9x
|
26.0x
|
| Revenue Growth YoY |
+8.6%
|
+16.4%
|
| Gross Margin |
83.7%
|
83.4%
|
| Operating Margin |
34.7%
|
59.2%
|
| Return on Equity |
-129.24%
|
198.4%
|
| Dividend Yield |
3.2% |
0.65% |
| FCF Yield |
4.78%
|
3.84%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Mastercard operates one of the world's two dominant payment networks, processing over $9 trillion in gross dollar volume annually across 220+ countries. The business generates 83% gross margins and 46% net margins with zero credit risk because Mastercard never lends money, only collecting tolls on every transaction. Value-Added Services (analytics, fraud prevention, cybersecurity) now comprise 41…
Accumulation Zones
| Metric |
ABBV |
MA |
| Zone Low |
$163.13 |
$460.00 |
| Zone High |
$184.88 |
$515.00 |
| In Buy Zone? |
No
|
Yes
|